They exemplify how a financialized business model that uses patents as a key tool to maximize profits and shareholder enrichment deepens structural health inequities
Highlights of Prescribing Information: WEGOVY (semaglutide) injection, for subcutaneous use
They are not a substitute for a varied and balanced diet and a healthy lifestyle
Nausea, vomiting, and other gastrointestinal symptoms are common, particularly when starting or increasing the dose and in T1D trials, these rates were similar to those seen in T2D and obesity trials
Tracking is emailed once its dispatched, transit time is carrier-dependent
Researchers who believe retatrutide will eventually receive FDA approval (currently projected no earlier than 2027) see bulk purchasing at current research peptide prices as an opportunity to work with the compound before commercial availability reshapes pricing and access